Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Swiss generic drugmaker Sandoz will pay up to $77 million ​upfront to Shanghai Henlius Biotech for rights to ‌three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties’ 2025 oncology biosimilars partnership SHANGHAI, Aug. 17, 2026 /PRNewswire/ — On August 17,…

Henlius partners with Sandoz for 10 biosimilar antibodies

SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an in…